Showing 8091-8100 of 9459 results for "".
- San Diego Dermatology Symposium Reschedules to Septemberhttps://practicaldermatology.com/news/san-diego-dermatology-symposium-reschedules-to-september/2460350/San Diego Dermatology Symposium will be held September 11-13, 2020, a shift from its original date. "The safety of our attendees, faculty, and exhibitors is our utmost priority, and we have been closely monitoring guidance from federal, state and local governments, as well as the World Healt
- Navigating the Ins and Outs of Your Insurance Coverage During COVID-19https://practicaldermatology.com/news/navigating-the-ins-and-outs-of-your-insurance-coverage-during-covid-19-1/2460349/Jason O’Dell, a financial consultant and insurance specialist at OJM Group, spoke with New Jersey-based dermatologist Jeanine Downie, MD and Chicagoland facial plastic surgeon Steve Dayan, MD about what to expect from insurance coverage during the pandemic and how to beef up your policies i
- New Melanoma Test May Reduce Unnecessary Lymph Node Biopsieshttps://practicaldermatology.com/news/new-melanoma-test-may-reduce-unnecessary-lymph-node-biopsies-1/2460348/A new skin cancer test may reduce up to 42 percent of sentinel lymph node biopsies used in the diagnosis of patients with melanoma, researchers at SkylineDx and Mayo Clinic report. The study appears in
- COVID-19 By the Numbers: April 14 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-14-edition/2460346/The US may have already reached its peak for medical resource utilization associated with COVID-19, according to estimates from the Institute for Health Metrics and Evaluation (IHME), an independent population health resea
- Industry Responds to COVID-19: E.T. Browne Drug Co., Columbia University Medical Center, RealSelfhttps://practicaldermatology.com/news/industry-responds-to-covid-19-et-browne-drug-co-realself-hydrafacial-thrive-causemetics/2460345/E.T. Browne Drug Co. The manufacturer of Palmer' Cocoa Butter Formula and Coconut Oil Formula skin and hair care products is now producing medical-grade hand sanitizer to address widespread supply shortages in the wake of COVID-19. Initial production of the disinfectant sanit
- Cynosure Names David Long Global Chief Financial Officerhttps://practicaldermatology.com/news/cynosure-names-david-long-global-chief-financial-officer/2460343/David Long is Cynosure’s new Chief Financial Officer, effective immediately. Until recently, Long served as CFO at Corindus Vascular Robotics, Inc., where he brought the company public and, ultimately, navigated its strategic sale to Siemens.
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir
- COVID-19 By the Numbers: April 7 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-7-edition/2460341/The peak for medical resource utilization related to COVID-19 in the US is estimated to hit on April 15, and deaths will peak on April 16, according to the Institute for Health Metrics and Evaluation (IHME), an independent population health research center at UW Medicine at the University of
- Dupixent Significantly Improves Severe AD in Childrenhttps://practicaldermatology.com/news/dupixent-significantly-improves-severe-ad-in-children/2460338/Dupixent showed significant improvement in severe atopic dermatitis (AD) for children aged 6 to 11 Years, according to a Phase 3 study. In the trial, Dupixent combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related q
- Antimalarials for COVID-19: Will Demand Outweigh Supply?https://practicaldermatology.com/news/antimalarials-for-covid-19-will-demand-outweigh-supply/2460337/Chloroquine and hydroxychloroquine may help treat COVID-19, but if mass prophylaxis is advised it's possible that demand will outweigh the supply of antimalarials, say Italian doctors in a letter published online today in the Annals of the Rheumatic Diseases. The results of prelimin